Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Does the media refer more to RXRX or BPMC?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Blueprint Medicines. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 7 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.84 beat Recursion Pharmaceuticals' score of 0.49 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Blueprint Medicines	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RXRX or BPMC more profitable?

Blueprint Medicines has a net margin of -27.70% compared to Recursion Pharmaceuticals' net margin of -961.32%. Blueprint Medicines' return on equity of -64.60% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-961.32%	-74.70%	-54.02%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Which has preferable earnings and valuation, RXRX or BPMC?

Blueprint Medicines has higher revenue and earnings than Recursion Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.84M	36.30	-$463.66M	-$1.77	-2.97
Blueprint Medicines	$508.82M	16.28	-$67.09M	-$2.47	-51.93

Which has more volatility & risk, RXRX or BPMC?

Recursion Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.

Do analysts recommend RXRX or BPMC?

Recursion Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 33.21%. Blueprint Medicines has a consensus target price of $128.06, suggesting a potential downside of 0.16%. Given Recursion Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Recursion Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27

Do insiders & institutionals hold more shares of RXRX or BPMC?

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Recursion Pharmaceuticals beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks.